Delcath Systems reports Q4 EPS (48c), consensus (51c)

Reports Q4 revenue $540K, consensus $540K. “We have made tremendous progress since the January launch of HEPZATO KIT in the US,” said Gerard Michel, CEO. “We have successfully secured a product specific J-Code and, with over 90 preceptorships completed by healthcare professionals across approximately 20 institutions in the US, are on track to train and activate 20 sites by year end. Furthermore, we have strengthened our balance sheet with additional investment from senior management and existing investors. I am proud of the team’s success in providing access to a new treatment for patients suffering from metastatic uveal melanoma.”